The company estimates that approximately 100000 people in the US have the condition. No cure exists for AATD instead doctors treat the symptoms of the disorder or patients can receive weekly injections of the alpha1 antitrypsin protein. Airna is looking to develop a therapy that can correct the mutation that produces the errant protein